打开APP

J Clin Oncol:放射治疗后化疗可延缓癌症

  1. 化疗
  2. 放射
  3. 癌症

来源:生物谷 2014-11-18 13:26

2014年11月18日讯 /生物谷BIOON/ --对于成人低级别胶质瘤(脑肿瘤的一种形式),相对于单纯放射治疗给药,放射治疗后接着化疗方案(包括甲基苄肼,洛莫司汀和长春新碱(PCV))能改善患者无进展生存期和总生存期。该

2014年11月18日讯 /生物谷BIOON/ --对于成人低级别胶质瘤(脑肿瘤的一种形式),相对于单纯放射治疗给药,放射治疗后接着化疗方案(包括甲基苄肼,洛莫司汀和长春新碱(PCV))能改善患者无进展生存期和总生存期。

该研究结果是一项III期临床试验的结果的一部分。Buckner博士说:平均而言,比那些单独接受放射治疗的患者,受到PCV治疗的患者存活长5.5年。这些研究结果发表在Journal of Clinical Oncology杂志上,研究结果表明在初次诊断时给予PCV与放射治疗,可延长无进展生存,但对整体生存没有影响。

入选实验RTOG9802的有251例低级别胶质瘤(自1998年10月2002年6月间),以解决放射治疗后化疗的作用。相比其他低级别胶质瘤患者,入选患者均在高风险,因为他们是40岁以上的老年人,或虽然他们在40岁以下但肿瘤没有完整手术切除。

调查人员还发现,较星形细胞瘤或少突星形细胞瘤而言,少突胶质细胞患者有更好的结果。他说,下一个步骤是利用参与患者的肿瘤组织,以确定生物标记物,这将允许研究人员能够确定哪些患者将从特定疗法中受益最多。(生物谷Bioon.com)

Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02

Roshan S. Prabhu, et al.

Purpose The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS). The effect of therapy intensification on cognitive function (CF) remains a concern in this population with substantial long-term survival.

Patients and Methods A total of 251 patients with WHO grade 2 glioma age ≥ 40 years with any extent of resection or age < 40 years with subtotal resection/biopsy were randomly assigned to RT (54 Gy) or RT plus PCV. We observed 111 patients age < 40 years with gross total resection. CF was assessed by Mini–Mental State Examination (MMSE) at baseline and years 1, 2, 3, and 5.

Results Overall, few patients experienced significant decline in MMSE score. There were no significant differences in the proportion of patients experiencing MMSE score decline between the randomized study arms at any time point. Both study arms experienced a significant gain in average MMSE score longitudinally over time, with no difference between arms.

Conclusion The MMSE is a relatively insensitive tool, and subtle changes in CF may have been missed. However, the addition of PCV to RT did not result in significantly higher rates of MMSE score decline than RT alone through 5 years of follow-up. Patients in both randomly assigned arms experienced a statistically significant average MMSE score increase over time, with no difference between arms. The addition of PCV chemotherapy to RT improves PFS without excessive CF detriment over RT alone for patients with low-grade glioma.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->